Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3-9 Years: A Phase II Study


Por: Ballester, A, Garces-Sanchez, M, Cantarino, M, Drame, M, Bouveret, N, Gillard, P and Diez-Domingo, J

Fecha de Publicación: 01/12/2008
Resumen:


Direcciones
Ballester, A: Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Garces-Sanchez, M: Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Cantarino, MVP: Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Drame, M: GlaxoSmithKline Biol, Rixensart, Belgium
Bouveret, N: GlaxoSmithKline Biol, Rixensart, Belgium
Gillard, P: GlaxoSmithKline Biol, Rixensart, Belgium
Diez-Domingo, J: Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
ISSN: 12019712





INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Editorial
ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Meeting Abstract
Volumen: 12 Número:
Páginas: 146-146s
WOS: 000263287800363

MÉTRICAS